IL36G and atopic eczema: Docking of Ambrisentan and Teneligliptin with IL‐36G confirmed their binding energies were also less than −5.0 kcal/mol (Figure 6D,E), demonstrating that these small‐molecule drugs can bind to IL‐36G and exert potential therapeutic effects, making them promising candidates for treating atopic dermatitis and psoriasis.